Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Aptevo Therapeutics revenue
Aptevo Therapeutics's revenue is $3.1 million.
What is Aptevo Therapeutics's revenue?
- Aptevo Therapeutics's revenue growth from 2015 to 2022 is -90.73%.
- Aptevo Therapeutics has 58 employees, and the revenue per employee ratio is $53,689.
- Aptevo Therapeutics's peak quarterly revenue was $10.2M in 2016(q2).
- Aptevo Therapeutics peak revenue was $33.6M in 2015.
- Aptevo Therapeutics annual revenue for 2021 was 12.3M, 185.26% growth from 2020.
- Aptevo Therapeutics annual revenue for 2022 was 3.1M, -74.67% growth from 2021.
On this page
Zippi applies for you, and finds you a job.
Aptevo Therapeutics historical revenue
Aptevo Therapeutics's peak revenue was $33.6M in 2015. The peak quarterly revenue was $10.2M in 2016(q2).
Aptevo Therapeutics's revenue increased from $33.6m in 2015 to $3.1M currently. That's a -90.73% change in annual revenue.
Aptevo Therapeutics annual revenue
Aptevo Therapeutics annual revenue over time
| Fiscal year / year | Aptevo Therapeutics revenue |
|---|---|
| 2015 | $33.6M |
| 2016 | $10.0M |
| 2017 | $14.7M |
| 2018 | $23.1M |
| 2020 | $4.3M |
| 2021 | $12.3M |
| 2022 | $3.1M |
Rate Aptevo Therapeutics' financial transparency
Aptevo Therapeutics annual growth
Aptevo Therapeutics saw the greatest revenue growth in 2021, when revenue increased by 185.26%.
Aptevo Therapeutics had the lowest revenue growth in 2020, when revenue changed by -81.32%.
Aptevo Therapeutics annual growth rate over time
| Year | Aptevo Therapeutics growth |
|---|---|
| 2016 | -70%↓ |
| 2017 | 47%↑ |
| 2018 | 57%↑ |
| 2020 | -81%↓ |
| 2021 | 185%↑ |
| 2022 | -75%↓ |
Aptevo Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Aptevo Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2016 | - | $10.2M | $2.8M | $2.8M |
| 2017 | $2.1M | $3.5M | $6.2M | $2.8M |
| 2018 | $4.1M | $6.8M | $5.8M | $6.3M |
| 2020 | - | $473,000 | $1.5M | $2.4M |
| 2021 | $2.4M | $3.1M | $3.1M | $3.7M |
| 2022 | $3.1M | - | - | - |
Aptevo Therapeutics jobs nearby
Do you work at Aptevo Therapeutics?
Is Aptevo Therapeutics transparent about its revenue structure?
Aptevo Therapeutics financial information
| CEO | Marvin L. White |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 58 |
| Date Founded | 2016 |
| Headquarters | Seattle, Washington |
| Number of Locations | 1 |
| Revenue | $3.1M |
| Net Income | $8,027,000 |
| Gross Proft | $11.9M (2018) |
| Tax Rate | -1.0% |
| Total Assets | $34,215,000 |
| Ticker | APVO |
Aptevo Therapeutics jobs you might like
Aptevo Therapeutics financing
Aptevo Therapeutics received early financing of $35.0M on 2016-08-01.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Debt | $35M | 08/2016 |
Aptevo Therapeutics competitors
Aptevo Therapeutics's top competitor, Blueprint Medicines, earned an annual revenue of $508.8M.
Aptevo Therapeutics's smallest competitor is NeuroMetrix with revenue of $5.9M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Blueprint Medicines | - | $508.8M | 495 | - |
| MacroGenics | - | $150.0M | 307 | - |
| Pharmion | - | - | 417 | - |
| VasoHealthcare | - | $8.0M | 96 | - |
| NeuroMetrix | - | $5.9M | 23 | - |
| Ep Global Communications | - | - | 15 | - |
| AlterG | - | $10.0M | 60 | - |
| Conceptus | - | $140.7M | 125 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Aptevo Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Aptevo Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Aptevo Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Aptevo Therapeutics. The data presented on this page does not represent the view of Aptevo Therapeutics and its employees or that of Zippia.
Aptevo Therapeutics may also be known as or be related to APTEVO THERAPEUTICS INC., Aptevo Therapeutics, Aptevo Therapeutics Inc, Aptevo Therapeutics Inc. and Aptevo Therapeutics, Inc.